ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0805 • ACR Convergence 2023

    De-escalation of Anti-TNFs in Older Adults with Rheumatoid Arthritis

    Jiha Lee1, Navasuja Kumar1, Mohammed Kabeto1, Andrzej Galecki1, Chiang-Hua Chang1, Namrata Singh2, Raymond Yung3, Una Makris4 and Julie Bynum1, 1University of Michigan, Ann Arbor, MI, 2University of Washington, Bellevue, WA, 3Michigan Medicine, Ann Arbor, MI, 4UT Southwestern Medical Center and Dallas VA, Dallas, TX

    Background/Purpose: Biologic disease modifying anti-rheumatic drugs (bDMARDs) such as anti-tumor necrosis factors(anti-TNFs) improve clinical and radiographic outcomes in rheumatoid arthritis (RA). However, their use is…
  • Abstract Number: 1117 • ACR Convergence 2023

    Serum Urate Change Among Gout Patients Initiating Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2i) vs. Sulfonylureas: A Comparative Effectiveness Analysis

    Chio Yokose1, Gregory Challener2, Baijun Zhou2, Natalie McCormick2, Sruthi Tanikella2, Kila Panchot2, Minna Kohler3, Janeth Yinh2, Yuqing Zhang4, David Bates5, James Januzzi2, Meghan Sise2, Deborah Wexler2 and Hyon K. Choi6, 1Massachusetts General Hospital, Waltham, MA, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital, Harvard Medical School, Boston, MA, 4Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, 5Brigham and Women's Hospital, Boston, MA, 6Massachusetts General Hospital and Harvard Medical School, Lexington, MA

    Background/Purpose: Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) are currently indicated as second-line therapy for type 2 diabetes and are also approved for the treatment of…
  • Abstract Number: 1132 • ACR Convergence 2023

    Preclinical Profiles of FZ007-119, a Highly Potent and Selective Tyk2 Inhibitor, for the Treatment of Immune Mediated Inflammatory Diseases

    Wenhe Zhong, Jielian Lu, Dong Chen, Shiqun Zhang and Daiguo Deng, Guangzhou Fermion Technology Co., LTD, Guangzhou, China

    Background/Purpose: Tyrosine Kinase 2 (TYK2) is a signaling protein within the Janus kinase (JAK) family. It plays a crucial role in transmitting signals from pro-inflammatory…
  • Abstract Number: 1260 • ACR Convergence 2023

    Optimal Approaches for Reducing Depressive Symptoms in Rheumatoid Arthritis Patients Based on Psychological Interventions: A Systematic Review and Network Meta-analysis

    Zhang Lijuan and Wu Beiwen, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    Background/Purpose: In recent years, numerous psychological interventions for rheumatoid arthritis (RA) patients have been developed. However, it remains unclear which psychological interventions are effective and…
  • Abstract Number: 1300 • ACR Convergence 2023

    Bone Marrow Edema in MRI Is More Associated with Rapid Radiographic Progression Than Clinically Relevant Radiographic Progression

    Kou Katayama1, Takanobu Okubo2, Toshikazu Sato1, Kitaru Tanaka3, Tomoki Kawahata3, Yuichi Makino4 and Hiroshi Ito5, 1Department of Orthopedic Surgery, Katayama Orthopedic Rheumatology Clinic, Asahikawa, Japan, 2Department of Radiology, Katayama Orthopedic Rheumatology Clinic, Asahikawa, Japan, 3Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan, 4Department of Medicine, Division of Rheumatology, Asahikawa Medical University Hospital, Asahikawa, Japan, 5Department of orthpedic surgery, Asahikawa Medical University, Asahikawa, Japan

    Background/Purpose: Rapid radiographic progression (RRP) is selected as one of the risk factors for difficult- to- treat RA, which needs to be resolved as soon…
  • Abstract Number: 0363 • ACR Convergence 2023

    Allogenic Hematopoietic Stem Cell Transplant for Children with Refractory Systemic Juvenile Idiopathic Arthritis and sJIA-Associated Lung Disease: 6-month Post-Transplant Outcomes from an International Cohort

    Michael Matt1, Daniel Drozdov1, Rolla Abu-Arja2, Shanmuganathan Chandrakasan3, Kyla Driest2, Elvira Cannizzaro Schneider4, Despina Moshous5, Benedicte Neven5, Karen Onel6, Sampath Prahalad7, Susan Prockop8, Pierre Quartier5, Johannes Roth9, Donna Wall10, Ulrike Zeilhofer11, Scott Canna12, Alexei Grom1, Grant Schulert1 and Rebecca Marsh1, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Nationwide Children's Hospital, Columbus, OH, 3Emory University School of Medicine, Atlanta, GA, 4Universitaetskinderspital Zurich, Zurich, Switzerland, 5Paris Cité Université and Necker Hospital, Paris, France, 6Hospital for Special Surgery, New York, NY, 7Emory University School of Medicine, Children's Pediatric Institute, Atlanta, GA, 8Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, 9University of Ottawa, Ottawa, ON, Canada, 10The Hospital for Sick Children, Toronto, ON, Canada, 11Children's Hospital of Zurich, Zurich, Switzerland, 12Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Refractory systemic juvenile idiopathic arthritis (sJIA) in children can be complicated by repeated episodes of macrophage activation syndrome (MAS) or sJIA-related lung disease (sJIA-LD).…
  • Abstract Number: 1302 • ACR Convergence 2023

    Biomarkers of Cardiovascular Risk in Patients with Rheumatoid Arthritis: Results from the TARGET Trial Biomarker Study

    Daniel Solomon1, Olga Demler2, Pamela Rist2, Leah Santacroce1, Jon Giles3, Katherine Liao1 and Joan Bathon3, 1Brigham and Women's Hospital, Boston, MA, 2Harvard Medical School, Boston, MA, 3Columbia University, New York, NY

    Background/Purpose: Cardiovascular (CV) disease remains an important source of morbidity and the most common cause of mortality in patients with rheumatoid arthritis (RA). It has…
  • Abstract Number: 1270 • ACR Convergence 2023

    Identification of Subclinical Atherosclerosis by Six Cardiovascular Risk Calculators in Rheumatoid Arthritis Patients

    Natalia Guajardo-Jauregui1, José Ramón Azpiri-López2, Dionicio A. Galarza-Delgado2, Iris Colunga2, Jesus Alberto Cardenas-De la Garza3 and Rosa Arvizu-Rivera4, 1Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico, 2Hospital Universitario UANL, Monterrey, Mexico, 3Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, 4Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico

    Background/Purpose: Current EULAR recommendations for cardiovascular risk (CVR) assessment in rheumatoid arthritis (RA) patients indicate that the CVR evaluation should be performed according to national…
  • Abstract Number: 1109 • ACR Convergence 2023

    Genetic Risk Variants in Hyperuricemia and Gout: Common Disease, Multiple Common and Rare Variant Hypothesis

    Blanka Stiburkova1, Katerina Pavelcova2, Jana Masinova1, Marketa Pavlikova3 and Karel Pavelka4, 1Institute of Rheumatology, Prague, Czech Republic, 2Institute of Rheumatology, Praha 2, Czech Republic, 3Department of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic, 4Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic

    Background/Purpose: Hyperuricemia is a central feature in the pathogenesis of gout. Hyperuricemia results from an imbalance between endogenous production and excretion of urate; however, the…
  • Abstract Number: 1263 • ACR Convergence 2023

    Depression and Anxiety Risk Assessment in Patients with Rheumatic Diseases

    Luis Vega Sevilla1, Miguel Villarreal-Alarcon2, Diana Paola Flores-Gutierrez3, Maria Corral-Trujillo4, Ricardo Juarez4, Ivan Hernandez Galarza5, Jesus Alberto Cardenas-De la Garza6 and Dionicio A. Galarza-Delgado2, 1Hospital Universitario UANL, Garcia, Mexico, 2Hospital Universitario UANL, Monterrey, Mexico, 3Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, 4Universidad Autónoma de Nuevo León, Monterrey, Mexico, 5University Hospital, UANL, San Pedro Garza Garcia, Mexico, 6Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico

    Background/Purpose: Depression is one of the most common psychiatric comorbidities in patients with rheumatic diseases. A study has shown that almost a third of patients…
  • Abstract Number: 1135 • ACR Convergence 2023

    The Prescribing Patterns and Role of TNF-α Inhibitors in Treatment of Cardiac Sarcoidosis Patients

    Alice Kwon1, Audrey Liu1, Sonali Narain2, Elena Katzap3 and Galina Marder2, 1Northwell Health, Manhasset, NY, 2Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 3Northwell Health, Great NY, NY

    Background/Purpose: Cardiac sarcoidosis is one of the most common causes of mortality from sarcoidosis. In this retrospective study, we describe prescribing patterns and compare outcomes between patients treated with conventional immunosuppressive therapies…
  • Abstract Number: 1128 • ACR Convergence 2023

    Refractory Inflammatory Ocular Pathology and Treatment with Janus Kinase Inhibitors. Multicenter Study and Literature Review

    Carmen Lasa-Teja1, Lara Sanchez-Bilbao2, Jose Luis Martin-Varillas3, Vanesa Calvo Río4, José Luis Álvarez-Vega5, Emma Beltran-Catalan6, María del Mar Esteban-Ortega7, Santiago Muñoz7, Olga Maiz8, Ignacio Torre-Salaberri9, Ana Urruticoechea10, Elia Valls-Pascual11, Raúl Veroz12, Carmen Alvarez Reguera13, Rosalía Demetrio13 and Ricardo Blanco14, 1Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology Group, Santander, Spain, 2Hospital Universitario Marques de Valdecilla, Santander, Spain, 3Hospital de Laredo, Laredo, Spain, 4Valdecilla Hospital, Santander, Spain, 5Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, 6HOSPITAL DEL MAR, Barcelona, Spain, 7Hospital Infanta Sofia, Madrid, Spain, 8Hospital Universitario de Donostia. San Sebastián, Spain., Donosti, Spain, 9Hospital Universitario de Basurto, Bilbao, Spain, 10Hospital Can Misses, Ibiza, Spain, 11Hospital Universitario Doctor Peset. Alicante, Spain., Valencia, Spain, 12Hospital de Mérida, Mérida. Spain., Mérida, Spain, 13Hospital Universitario Marqués de Valdecilla, Santander, Spain, 14Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Inflammatory ocular pathology (IOP) includes internal (uveitis) and external [mainly ocular surface pathology such as epi/scleritis and peripheral ulcerative keratitis (PUK)] involvement. IOP may…
  • Abstract Number: 1137 • ACR Convergence 2023

    Association Between Nailfold Videocapillaroscopy Findings and sKL-6 Levels in Patients with Idiopathic Inflammatory Myopathies–Related Interstitial Lung Disease

    Cristiana Sieiro Santos1, Jose Luis Tandaipan2, Diego Castillo2, Laura Martínez Martínez2, Helena Codes2, Luis Sainz-Comas2, Berta Paula Magallares-Lopez3, Patricia Moya2, Anais Mariscal2, Hye Sang Park2, Ana Milena Millán Arciniegas2, César Díaz-Torné2, Ana Laíz Alonso2, Sandra Ros2, Susana Fernández2, Hector Corominas4, Elvira Díez Álvarez5 and Iván Castellvi2, 1Complejo Asistencial Universitario de León, León, Spain, 2Hospital de Santa Creu i Sant Pau, Barcelona, Spain, 3Department of Rheumatology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, 4Hospital Universitario Sant Pau, Rheumatology, Barcelona, Spain, 5CAULE, León, Spain

    Background/Purpose: Interstitial lung disease (ILD) is a frequent pulmonary manifestation in idiopathic inflammatory myopathies (IIM) (IIM-ILD) and considerably influences morbidity and mortality. Krebs von den…
  • Abstract Number: 1269 • ACR Convergence 2023

    The Impact of Sex, Serostatus, and Smoking on Risk for Rheumatoid Arthritis-associated Interstitial Lung Disease Subtypes

    Gregory McDermott1, Keigo Hayashi1, Pierre-Antoine Juge2, Ritu Gill1, Suzanne Byrne1, Staci Gagne1, Kathleen Vanni1, Emily Kowalski1, Grace Qian1, Katarina Bade3, Alene Saavedra1, Yumeko Kawano1, Michael Diiorio3, Taylor Wolfgang1, Edy Kim1, Paul Dellaripa3, Michael Weinblatt4, Nancy Shadick3, Tracy J. Doyle1 and Jeffrey Sparks5, 1Brigham and Women's Hospital, Boston, MA, 2Division of Rheumatology, Inflammation, and Immunity Brigham & Women's Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Harvard Medical School, Waban, MA, 5Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: RA-associated interstitial lung disease (RA-ILD) is a heterogenous condition encompassing multiple subtypes with varying histopathology, prognosis, and potential treatment options. The most common RA-ILD…
  • Abstract Number: 1141 • ACR Convergence 2023

    COVID-19 Vaccination Status and Adverse Events Following SARS-CoV-2 Vaccine in Autoimmune Inflammatory Rheumatic Disease (AIRD) Patients: A Single Center Experience

    Vincent Luceño1, Peter Paolo Daleon1 and Sandra Navarra2, 1University of Santo Tomas Hospital, City of Manila, Philippines, 2University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines

    Background/Purpose: Autoimmune inflammatory rheumatic diseases (AIRD) were associated with an increased risk for COVID-19 infection, worse clinical outcomes, and COVID-19- related deaths. Vaccines carry the…
  • « Previous Page
  • 1
  • …
  • 250
  • 251
  • 252
  • 253
  • 254
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology